ONCAlert | Upfront Therapy for mRCC

Mantle Cell Lymphoma VIEW MORE >>

In an interview with Targeted Oncology, Ezzat Elhassadi, MD, discussed the results from this analysis and how the presence of a TP53 mutation can impact the survival of patients with MCL. He also highlighted the remaining challenges in this space and how these challenges can be overcome.

Latest JournalAll Journals >>

Evolving Paradigms Mantle Cell Lymphoma
Evolving Paradigms
MORE >>

The Targeted Oncology mantle cell lymphoma resource center serves as a hub for all clinical news and expert insights related to this rare subtype of non-Hodgkin lymphoma. Content found here includes video interviews with lymphoma experts and key opinion leaders in the field sharing their perspectives on existing mantle cell lymphoma treatment options and management approaches, including case studies that describe the clinical presentation and diagnostic criteria for patients with MCL.

This page also houses the most recent issue of Evolving Paradigms: Mantle Cell Lymphoma. This educational journal offers information regarding mantle cell lymphoma prognosis, staging, and risk, as well as current and emerging therapies for the disease.

Copyright © TargetedOnc 2019 Intellisphere, LLC. All Rights Reserved.